Following the FDA's decision to remove the clinical hold on Intellia's Nex-Z hATTR-PN trial, analysts at Baird and H.C. Wainwright have significantly raised their price targets for the CRISPR gene-editing pioneer, citing reduced regulatory risk and a clearer path forward.
Wells Fargo boosts its price target for Taysha Gene Therapies (TSHA), citing strong progress in its pivotal Rett syndrome gene therapy program. The company has dosed the first patient in a key trial phase and received FDA alignment on its regulatory pathway.
Analysts at Stifel have raised their price target for Nurix Therapeutics (NRIX) to $35, maintaining a Buy rating ahead of anticipated 2026 clinical milestones for its lead asset, bexobrutinib. The move comes as Wells Fargo also adjusted its target, highlighting divergent near-term views but shared long-term optimism for the biotech firm.
TD Cowen reaffirms its Buy rating on Dynatrace (DT) while adjusting its price target, anticipating stronger-than-expected performance driven by its new AI-powered observability platform, Dynatrace Intelligence.
The cryptocurrency wallet provider Exodus Movement reports disciplined capital management with a debt-free balance sheet and 1.5 million monthly users, even as BTIG trims its price target citing cautious volume outlook.
ABB's shares surged 10% following its annual results, with earnings per share exceeding forecasts. Analysts have raised their price target to CHF 60.30 and project accelerated revenue growth ahead of industry peers.
A revised analyst price target for Grupo Financiero Banorte (BMV:GFNORTE O) is refocusing investor attention on the Mexican banking giant, highlighting how evolving assessments of risk and growth potential can rapidly reshape a stock's narrative.
Amidst sluggish sales and intense competition, Target appoints Michael Fiddelke as CEO and refreshes its board, placing store revitalization and operational efficiency at the heart of its turnaround strategy.
Analysts at Piper Sandler have increased their price target for Permian Basin-focused producer Diamondback Energy (FANG) to $218, maintaining an Overweight rating. The move comes as the firm anticipates solid Q4 results for gas-focused companies, while oil producers navigate a tougher pricing environment.
Insurance brokerage giant Brown & Brown sees a key price target cut to $81 following its fourth-quarter earnings, which revealed robust fee growth but concerns over slowing organic revenue expansion.
Analyst Joe Laetsch raises HF Sinclair's price target, highlighting favorable crude differentials and a recent $38 million acquisition aimed at expanding its lubricants business, as the refiner lands on a list of top low-risk dividend stocks.
Seaport Research analyst Scott Graham lowered Badger Meter's price target to $220 from $255, citing a slower sales pace in early 2025. The firm maintains a Buy rating, anticipating a stronger second half. The water technology company recently reported record annual sales and profits.
Truist Securities raises its price target on Huntington Bancshares (HBAN) following a robust Q4 performance, as the regional bank forecasts record interest income growth and benefits from improving industry tailwinds.
Insurance brokerage giant Arthur J. Gallagher reported robust fourth-quarter profit growth, driven by resilient demand. However, Truist Securities has lowered its price target on the stock, citing valuation pressures across the property & casualty brokerage sector.
Barclays raises its price target on NorthWestern Energy Group (NWE) to $62, citing solid quarterly performance and strategic moves, including a pending merger with Black Hills Corporation, as the regulated utility reaffirms its long-term growth outlook.
UBS analyst Peter Grom increased his price target for Kimberly-Clark (KMB) to $110, citing steady core performance despite lingering Kenvue-related uncertainties, after the consumer goods giant reported better-than-expected quarterly profit driven by cost discipline and resilient demand.
TD Cowen raises Prudential Financial's price target to $113, maintaining a 'Hold' rating, as the insurer grapples with a misconduct scandal at its Japan life insurance unit affecting nearly 500 customers.
Stifel Nicolaus lowered its price target on Altria Group (MO) by $4 to $68, citing higher-than-expected operating costs. Despite near-term headwinds, the firm reaffirmed its Buy rating, pointing to the tobacco giant's resilient dividend profile and long-term earnings guidance.
Scotiabank has lowered its price target for Comcast (CMCSA), reflecting ongoing pressure in its core broadband business as the media giant reports higher-than-expected customer losses in Q4 and faces fierce competition from fiber and fixed-wireless rivals.
Wells Fargo lowered its price target on UnitedHealth Group (UNH) following its Q4 report and a disappointing Medicare rate proposal from regulators, highlighting pressures on the healthcare giant's key growth engine.
